Product Sheet

ADORA2A Antagonist Antibodies for Immuno- Oncology, Primed for Development

Tap into the next generation of immune checkpoint inhibition for broad cancer indications.

Checkpoint inhibitors have quickly become a cornerstone in the treatment of numerous cancers, but are only effective for 20–30% of eligible patients. Patients with certain cancers, such as non-small cell lung cancer (140K patients), prostate cancer (75K patients), and colorectal cancer (85K patients), have limited options beyond chemotherapy and some targeted therapies if they are resistant to first generation checkpoint inhibitors.